GREGORY PANICCIA: Open Payments
NPI 1518022920 · NATIONAL CITY, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,908 in 240 payments from 14 companies in 2025. Trend: 2023 $3,438 · 2024 $3,068 · 2025 $4,908
Food & beverage: $4,794Education: $114
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 43 | $823 |
| Alkermes, Inc. | 36 | $693 |
| Otsuka America Pharmaceutical, Inc. | 29 | $665 |
| ABBVIE INC. | 26 | $529 |
| Teva Pharmaceuticals USA, Inc. | 22 | $512 |
| E.R. Squibb & Sons, L.L.C. | 25 | $388 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $351 |
| Vanda Pharmaceuticals Inc. | 13 | $278 |
| Janssen Pharmaceuticals, Inc | 12 | $231 |
| Lundbeck LLC | 10 | $213 |
Products named: INGREZZA, REXULTI, ARISTADA, VRAYLAR, COBENFY, CAPLYTA, UZEDY, FANAPT.
Industry payments across CA — which companies pay providers there.
